These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11679856)

  • 21. Progressive systemic sclerosis.
    Medsger TA
    Clin Rheum Dis; 1983 Dec; 9(3):655-70. PubMed ID: 6360519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of scleroderma].
    Mouthon L
    Rev Prat; 2002 Nov; 52(17):1915-7. PubMed ID: 12532869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic management of acral manifestations of systemic sclerosis].
    Meyer MF; Daigeler A; Lehnhardt M; Steinau HU; Klein HH
    Med Klin (Munich); 2007 Mar; 102(3):209-18. PubMed ID: 17345017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment options for the cutaneous manifestations of systemic sclerosis.
    Dutz J
    Skin Therapy Lett; 2000; 6(1):3-5. PubMed ID: 11027421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasoactive therapies in systemic sclerosis.
    Riemekasten G; Sunderkötter C
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii49-51. PubMed ID: 16987836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapy for systemic sclerosis.
    Steen V
    Autoimmun Rev; 2006 Feb; 5(2):122-4. PubMed ID: 16431341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Systemic sclerosis].
    Tamborrini G; Distler M; Distler O
    Med Monatsschr Pharm; 2008 May; 31(5):162-70; quiz 171-2. PubMed ID: 18552072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of efficacy of quinapril on vascular damage in limited cutaneous systemic sclerosis.
    Guiducci S; Cerinic MM
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):288-9. PubMed ID: 18461063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
    Henness S; Wigley FM
    Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A.
    Basso M; Filaci G; Cutolo M; Murdaca G; Derchi L; Gianrossi R; Ropolo F; Zentilin P; Sulli A; Puppo F; Indiveri F
    Ann Ital Med Int; 2001; 16(4):233-9. PubMed ID: 11799631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors.
    Sunderkötter C; Herrgott I; Brückner C; Moinzadeh P; Pfeiffer C; Gerss J; Hunzelmann N; Böhm M; Krieg T; Müller-Ladner U; Genth E; Schulze-Lohoff E; Meurer M; Melchers I; Riemekasten G;
    Br J Dermatol; 2009 Apr; 160(4):835-43. PubMed ID: 19183180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and management of scleroderma peripheral vascular disease.
    Herrick A
    Rheum Dis Clin North Am; 2008 Feb; 34(1):89-114; vii. PubMed ID: 18329535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pulmonary arterial hypertension in connective tissue disease].
    Cottin V
    Rev Mal Respir; 2006 Sep; 23(4 Suppl):13S61-72. PubMed ID: 17057632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment.
    Villela R; Yuen SY; Pope JE; Baron M;
    Arthritis Rheum; 2008 May; 59(5):706-13. PubMed ID: 18438906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.